Wilex Renal Cell Carcinoma 124IcG250 Clinical Imaging Trial

1
Wilex Renal Cell Carcinoma 124I-cG250 Clinical
Imaging Trial
The Nevada Cancer Institute (NVCI) is the first
site in the United States participating in the
clinical trial WX/20-001 to use 124I-labeled
antibody (cG250) positron emission tomography
(PET) imaging (Wilex AG, Munich, Germany). An
antibody is a protein found in blood and bodily
fluids that is used by the immune system to
identify and neutralize foreign bodies (in this
case, kidney cancer cells). The antibody is
linked to a radioactive imaging tracer, an
isotope of Iodine (124I). The radiolabeled
antibody (124I-cG250) is injected into the body
and binds preferentially to the clear cell form
of renal cell carcinoma (ccRCC). The radiotracer
emits positrons that annihilate with electrons to
form pairs of gamma rays. The gamma rays are
detected by the PET scanner to form an image.
The physicians can use the PET images to
determine the location and type of the renal
carcinoma cells, prior to treatment or surgery.
The PET tracer can also detect ccRCC metastases
that have spread from the kidneys to other
locations in the body. The PET images are
acquired with x-ray based computer tomography
(CT) scans of the anatomy to assist the physician
in locating the suspected lesion. Greater than
60 of renal masses are clear cell renal cell
carcinoma (ccRCC). ccRCC is an aggressive form
of kidney cancer with a poor prognosis.
Coronal View
Axial View
124I-cG250 PET/CT scans. The PET images were
acquired 7 days after 5.2 mCi of the
radio-labeled tracer were injected into the
patient. The PET images (colored pixels) are
shown fused with the CT structural scans (black
and white). The increased signal in the left
kidney (yellow arrow) compared to the right
kidney is indicative of increased 124I-cG250
binding and a marker for ccRCC tumor activity.
Left Kidney
Right Kidney
Left
Right